MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-14-2023
Navidea Biopharmaceuticals ROE Ratio 2011-2026 | NAVB
Annual ROE Ratio Navidea Biopharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 179.91 | 11009.17 | -814.96 | 679.05 | -924.95 | 658.6 | 21.0 | 50.76 | 119.87 | 1064.93 | 2074.69 | 26.56 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11009.17 | -924.95 | 1178.72 |
Quarterly ROE Ratio Navidea Biopharmaceuticals
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -352.29 | -298.91 | 330.79 | 334.64 | 275.67 | 94.4 | -17.87 | -159.75 | -380.13 | -541.54 | -676.77 | -600.38 | -409.71 | 1.34 | 343.91 | 507.13 | 287.75 | -122.3 | -425.52 | -743.56 | -779.22 | -572.05 | -480.22 | 658.6 | 699.96 | 712.25 | 767.64 | 21.0 | 19.93 | 34.7 | 42.74 | 50.76 | 69.17 | 77.45 | 93.91 | 119.87 | 439.82 | 698.64 | 921.23 | 1064.92 | 1234.48 | 1599.92 | 1758.21 | 2072.43 | 1653.75 | 1100.19 | 674.65 | 62.56 | 93.85 | -10.36 | -20.93 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2072.43 | -779.22 | 241.7 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-36.22 | $ 3.6 | 1.34 % | $ 8.66 B |  Australia |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.66 | - | $ 16.7 M |  USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 91.28 | - | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Burford Capital Limited
BUR
|
10.1 | $ 4.48 | - | $ 736 M |  Britain |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Cerus Corporation
CERS
|
-24.33 | $ 1.85 | - | $ 353 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Coherus BioSciences
CHRS
|
275.39 | $ 1.67 | - | $ 196 M | USA |
 |
Celldex Therapeutics
CLDX
|
-49.08 | $ 31.37 | - | $ 2.08 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-123.35 | $ 0.44 | - | $ 5.04 M |  Israel |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-350.48 | $ 2.32 | - | $ 1.03 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Catalyst Pharmaceuticals
CPRX
|
22.46 | $ 24.98 | - | $ 3.05 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-53.24 | $ 10.14 | - | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
-101.02 | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
-138.81 | $ 0.53 | - | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-46.9 | $ 37.7 | - | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-30.26 | $ 49.15 | - | $ 4.42 B |  Schweiz |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
CytomX Therapeutics
CTMX
|
-17.54 | $ 4.4 | - | $ 607 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-56.26 | $ 0.86 | - | $ 5.79 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Cue Biopharma
CUE
|
-100.64 | $ 0.18 | - | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-87.07 | $ 20.36 | - | $ 2.84 B | France |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
Denali Therapeutics
DNLI
|
-34.38 | $ 19.38 | - | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
-597.58 | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
-61.06 | $ 3.54 | - | $ 238 B | Britain |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Entera Bio Ltd.
ENTX
|
-149.78 | $ 1.19 | - | $ 55.5 M | Israel |
 |
Equillium
EQ
|
-78.32 | $ 2.01 | - | $ 115 M | USA |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
39.76 | $ 330.34 | - | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Fate Therapeutics
FATE
|
-65.79 | $ 1.19 | - | $ 141 M | USA |
 |
Aileron Therapeutics
ALRN
|
-294.78 | - | 10.36 % | $ 9.8 M | USA |